Janssen’s Multiple Myeloma Gene Therapy On Track For EU-Wide Approval

CHMP Recommends Six Extensions Of Indications For Approved Medicines

The European Medicines Agency’s human medicines committee has recommended five new drugs for use in the EU at its latest monthly meeting.

Multiple myeloma cells emitting M (Monoclonal) protein in the blood flow - isometric view 3d illustration
Multiple myeloma is an incurable blood cancer that starts in the bone marrow • Source: Alamy

Janssen’s gene therapy for multiple myeloma patients, Carvykti (ciltacabtagene autoleucel), has been recommended for conditional EU-wide approval.

Carvykti is a CAR-T therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies. Approved in the US last month,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>